MCLA-129 by Merus for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

MCLA-129 is under clinical development by Merus and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase II drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MCLA-129’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MCLA-129 overview

MCLA-129 is under development for the treatment of solid tumor including non-small cell lung cancer, gastric cancer, esophageal squamous cell cancer (ESCC), gastroesophageal junction (GC/GEJ) adenocarcinoma, head and neck cancer and colorectal cancer. It is administered through intravenous drip. The therapeutic candidate is a bi-specific monoclonal antibody that acts by targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET). The drug candidate is being developed based on Biclonics platform.

Merus overview

Merus is a pharmaceutical company that discovers and develops antibody therapeutics for cancer indications. The company is investigating MCLA-128, for the treatment of metastatic breast cancer and solid tumors; ONO-4685, for the treatment of autoimmune disease. It is also evaluating MCLA-158 and MCLA-129, to treat solid tumors and MCLA-145, a T-cell agonist targeting hematological malignancy and solid tumors. Merus utilizes Multiclonics, Biclonics and Triclonics technology platform for developing antibodies to treat cancer. The company works in collaboration with Incyte Corporation, Simcere Pharmaceutical Group, Ono Pharmaceutical Co., Ltd. and Betta Pharmaceuticals Co Ltd to advance its pipeline products. Merus is headquartered in Utrecht, the Netherlands.

For a complete picture of MCLA-129’s drug-specific PTSR and LoA scores, buy the report here.